Arcus Biosciences Inc (RCUS) Given Average Recommendation of “Strong Buy” by Analysts

Shares of Arcus Biosciences Inc (NYSE:RCUS) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price objective of $21.50 for the company and are predicting that the company will post ($0.39) earnings per share for the current quarter, according to Zacks. Zacks has also given Arcus Biosciences an industry rank of 156 out of 255 based on the ratings given to its competitors.

A number of research firms have recently issued reports on RCUS. Zacks Investment Research raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. Leerink Swann began coverage on Arcus Biosciences in a research report on Monday, April 9th. They set an “outperform” rating and a $21.00 price target on the stock. Goldman Sachs Group began coverage on Arcus Biosciences in a research report on Monday, April 9th. They set a “neutral” rating and a $18.00 price target on the stock. Finally, Citigroup assumed coverage on Arcus Biosciences in a research report on Monday, April 9th. They set a “buy” rating and a $18.00 price target on the stock.

Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN purchased a new stake in Arcus Biosciences in the first quarter valued at about $155,000. Dean Capital Investments Management LLC purchased a new position in shares of Arcus Biosciences in the first quarter worth about $303,000. BVF Inc. IL purchased a new position in shares of Arcus Biosciences in the first quarter worth about $19,606,000. BlackRock Inc. purchased a new position in shares of Arcus Biosciences in the first quarter worth about $303,000. Finally, Artal Group S.A. purchased a new position in shares of Arcus Biosciences in the first quarter worth about $4,632,000. 33.24% of the stock is currently owned by institutional investors.

RCUS stock traded down $0.38 during midday trading on Friday, reaching $15.64. The company’s stock had a trading volume of 188 shares, compared to its average volume of 152,208. Arcus Biosciences has a 1 year low of $13.26 and a 1 year high of $22.10.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.49). The firm had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.30 million. sell-side analysts predict that Arcus Biosciences will post -1.82 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

Get a free copy of the Zacks research report on Arcus Biosciences (RCUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply